Latigo Biotherapeutics

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative non-opioid pain medicines. The company's drug candidates target the Nav1.8 sodium ion channel to stop the transmission of pain without the risk of addiction. Its lead product candidate, onzotrigine (formerly LTG-001), is an oral Nav1.8 inhibitor for acute pain that demonstrated statistically significant pain relief in a Phase 2 abdominoplasty trial and is advancing to Phase 3 studies. LTG-321 is an oral Nav1.8 inhibitor being developed for chronic musculoskeletal pain, currently in a Phase 2 trial for knee osteoarthritis. The company is also advancing LTG-418, a next-generation Nav1.8 inhibitor designed for low-dose administration enabling alternative formulations and delivery approaches, as well as conducting discovery research on additional ion channel targets for pain, including neuropathic pain. Latigo completed its IPO on Nasdaq in August 2026, raising gross proceeds of approximately $397.4 million. The company trades under the ticker LTGO. Updated Sep 3, 2026